General – VJRegenMed

Multivalent gamma-delta T-cells: promising agents for the treatment of cancers

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

In this video, Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, The Netherlands, briefly discusses the promise of novel gamma delta T-cells, which are being explored for the treatment of various cancers and have shown promising pre-clinical results. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Rapid CAR-T manufacturing and challenges in this space

Anya Kerkache — Wed, 08 Mar 2023 10:35:16 +0000

Nina Worel, MD, Medical University of Vienna, Vienna, Austria, shares some insights into challenges with CAR-T manufacturing, explaining that even rapid manufacturing processes may require patients to wait up to four weeks before they can receive treatment. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

An insight into novel third-generation TLR2 co-stimulatory CAR-T cells

Anya Kerkache — Wed, 08 Mar 2023 10:35:15 +0000

In this video, Yasmin Nouri, BSc, MSc, Malaghan Institute of Medical Research, Wellington, New Zealand, shares some insights into the development of a novel third-generation TLR2 co-stimulatory CAR-T cell product for the treatment of B-cell malignancies, which has demonstrated promising activity in a Phase I clinical trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Streamlining cell therapy manufacturing with CliniMACS Prodigy

Simon Ng — Thu, 28 Apr 2022 08:38:41 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, gives an overview of CliniMACS Prodigy, a novel next-generation automated cell processing platform that aims to separate and process cell cultures for the manufacturing of cell therapies. The closed, scalable system enables the production of good manufacturing practice (GMP) compliant products of consistent quality in a safe and clean environment. CliniMACS Prodigy additionally is flexible in a centralized or decentralized setting and can be used for various cell types including induced pluripotent stem (iPS) cells, chimeric antigen receptor (CAR) T-cells and natural killer (NK) cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Implementing automation technology in the CGT space

Simon Ng — Thu, 28 Apr 2022 08:38:40 +0000

The advent of automation has brought improvements in the manufacturing of advanced therapies in terms of reducing the number of staff needed, cost, and safety. Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, discusses potential barriers developers might face in automating their manufacturing processes. Companies will need to make sure the product can be translated from a research to clinical setting, as well as if the reagents can be scaled-up if necessary. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Utilizing flow cytometry in CAR T-cell research

Simon Ng — Thu, 28 Apr 2022 08:38:38 +0000

Saskia Rösch, PhD, Miltenyi Biotec, Bergisch Gladbach, Germany, comments on the importance of flow cytometry in the characterization of chimeric antigen receptor (CAR) T-cells. Standardization of flow cytometry techniques is necessary to optimize CAR T-cell therapies, and Dr Rösch discusses automated workflow solutions offered by Miltenyi, as well as CAR detectors that can quantify CAR T-cells in a given sample. She additionally highlights a consortium that will create a gold standard for the analysis of engineered CAR T-cells. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

Applications of stem cell gene therapy beyond genetic diseases

admin_vjr_user — Fri, 22 Apr 2022 12:21:18 +0000

Luigi Naldini, MD, PhD, San Raffaele Telethon Institute for Gene Therapy, Milano, Italy, comments on the potential application of stem cell gene therapy in oncology. In recent years, growing evidence supporting the efficacy and tolerability of this technology in genetic diseases has suggested it as a promising strategy to target tumors by engineering stem cells to target the tumor or to deliver a therapeutic agent. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR® 2022 in Salt Lake City, Utah.

Addressing challenges in using MSCs in cell therapies

Simon Ng — Thu, 21 Apr 2022 15:04:28 +0000

Mesenchymal stem cells (MSCs) have demonstrated potential in cell therapies, as they have unique immunomodulatory properties. Ross Macdonald, PhD, Cynata Therapeutics, Melbourne, Australia, comments on the hurdles in commercializing MSC-based cell therapies. Unlike autologous chimeric antigen receptor (CAR) T-cell therapies, MSCs are derived from allogeneic sources, which in itself presents logistical issues in terms of obtaining enough donors. Cell expansion for commercial usage additionally is an issue, as MSCs become less potent as they expand, and Dr Macdonald presents solutions offered by Cynata Therapeutics that attempt to overcome the aforementioned barriers. This interview was conducted during Meeting on the Mediterranean 2022.

Generating iSPC-derived MSCs with the Cymerus™ Platform

Simon Ng — Thu, 21 Apr 2022 15:04:27 +0000

Ross Macdonald, PhD, Cynata Therapeutics, Melbourne, Australia, discusses the process of manufacturing mesenchymal stem cells (MSCs) derived from induced pluripotent stem cells (iPSCs) with the Cymerus Platform. MSCs have shown encouraging efficacy as cell therapies and using iPSCs enables the MSCs to remain potent, as they do not require expansion. The iSPCs also do not require multiple donors as they can replicate indefinitely, resulting in MSCs of a consistent quality. This interview was conducted during Meeting on the Mediterranean 2022.

Meeting the growing demand for gene therapy manufacturing

Simon Ng — Wed, 20 Apr 2022 16:45:45 +0000

John Maslowski, CCO, Forge Biologics, Columbus, OH, gives an overview of Forge Biologics’ plans to meet the increasing demand for gene therapies. The recent $80 million expansion of the manufacturing facilities at Forge Biologics with automated components and clean rooms will enable global expansion. Additional recruitment of personal and inhouse analytical services will also enhance current adeno-associated virus (AAV) vector production capabilities. This interview took place at Advanced Therapies Week 2022.